

| | | |
|--|--|---|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | ATTY. DOCKET NO. MGH-028AUS | APPLICATION NO. 10/814,852 |
| | APPLICANT Maurizio Fava, et al. | |
| | FILING DATE March 31, 2004 | GROUP 3626 |

Page 1 of 1

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|--|-----------------|------|------|-------|---------------|--------------------------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE* |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OFFICE OF PETITIONS

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--|-----------------|------|------|-------|-----------|-------------|----|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) | | |
|---|-----------------|--|
| /E.S./ | | Brown, Jr.; "The Crossover Experiment for Clinical Trials;" Publication of Stanford University Medical Center, Stanford, CA; Biometrics 36; March 1980; pages 69-79 |
| /E.S./ | | Carriere; "Crossover Designs for Clinical Trials;" Statistics in Medicine; Vol. 13; April 1993; pages 1063-1069 |
| /E.S./ | | Farlow et al.; "A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer's Disease;" European Neurology; Vol. 4, November 2000; pages 236-241 |
| /E.S./ | | Hills et al.; "The Two-Period Cross-Over Clinical Trial;" British Journal of Clinical Pharmacology; July 1979; pages 7-20 |
| /E.S./ | | Leber et al.; "Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection;" Elsevier Science Inc.; Controlled Clinical Trials; Vol. 19, Issue 2 April 1998; pages 178-187 |
| /E.S./ | | Raskind et al.; "Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension;" American Academy of Neurology; June 2000; pages 2260-2269 |
| /E.S./ | | Rosner et al.; "Randomized Discontinuation Design: Applied to Cytostatic Antineoplastic Agents;" Journal of Clinical Oncology; Vol. 20, No. 22; November 15, 2002; pages 4478-4484 |
| /E.S./ | | Temple; "Special Study Designs: Early Escape, Enrichment, Studies in Non-Responders;" Communications in Statistics-Theory and Method; Vol. 23, Issue 2; 1994; pages 499-531 |
| | | |
| | | |
| Examiner | /Eliza Squires/ | Date Considered: 10/07/2009 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant. | | |